Target Name: TERF2
NCBI ID: G7014
Review Report on TERF2 Target / Biomarker Content of Review Report on TERF2 Target / Biomarker
TERF2
Other Name(s): TTAGGG repeat-binding factor 2 | Telomeric repeat binding factor 2 | Telomeric repeat binding protein 2 | TERF2_HUMAN | TRF2 | telomeric repeat binding factor 2 | telomeric repeat binding protein 2 | telomeric DNA-binding protein | Telomeric DNA-binding protein | Telomeric repeat-binding factor 2 | TRBF2

TERF2: A Potential Drug Target and Biomarker for Chronic Pain

Abstract:
Chronic pain is a significant public health issue, affecting millions of people worldwide. The persistent nature of pain can lead to significant morbidity and disability, making it an attractive target for drug development. TERF2, a non-coding RNA molecule, has been identified as a potential drug target and biomarker for chronic pain. This article summarizes the current understanding of TERF2, its potential drug targeting properties, and its role as a biomarker for chronic pain.

Introduction:
Chronic pain is a persistent and often debilitating condition that can significantly impact an individual's quality of life. The World Health Organization (WHO) estimates that approximately 50% of the global population experiences chronic pain, with costs associated with chronic pain reaching $60 billion annually. Chronic pain can arise from a variety of underlying conditions, including neuropathic pain, rheumatoid arthritis, and cancer-related pain. The management of chronic pain is often challenging, and the search for new treatments has led to the development of novel drug targets and biomarkers.

background:
Chronic pain is a global public health problem affecting thousands of people. Persistent pain can cause significant morbidity and disability, making it an attractive target for drug development. TERF2, a noncoding RNA molecule, has been identified as potentially valuable as a drug target or biomarker. This article provides an overview of the current understanding of TERF2, its drug target properties, and its role as a biomarker in chronic pain.

Basic understanding of TERF2:
TERF2 (Transcriptional start regulation factor 2) is a non-coding RNA molecule whose coding region is located on human chromosome 1p36.1. TERF2 functions by binding to DNA-binding proteins to regulate gene expression. The RNA binding site (RBP) and core RNA binding site (CRBP) domains of TERF2 are considered to be critical parts of TERF2 function. The RBP domain of TERF2 binds histone H3K9me3, while CRBP binds histone H3K4me1. This binding facilitates DNA binding of TERF2, thereby affecting gene expression.

Drug target properties of TERF2:
The drug target properties of TERF2 make it an attractive drug target. The RNA-binding site domain of TERF2 enables it to bind histones, which provides a basis for the development of anti-histone drugs. In addition, the CRBP domain of TERF2 also makes it easy to interact with proteins, thus increasing the interaction between drug targets. The drug target properties of TERF2 make it a promising drug target.

Biomarker properties of TERF2:
The biomarker properties of TERF2 make it an attractive biomarker. The expression level of TERF2 can be used as a measure of chronic pain severity and pain type. TERF2 expression levels are also closely related to patients' quality of life and health status, making TERF2 an attractive biomarker. In addition, the expression level of TERF2 can also be used as an indicator of therapeutic efficacy, which provides a basis for studying drugs to treat chronic pain.

Clinical application prospects of TERF2:
The drug target and biomarker properties of TERF2 provide promise for its clinical application in the treatment of chronic pain. TERF2 serves as a novel drug target that could lead to the development of drugs with analgesic effects and long-term relief. In addition, T

Protein Name: Telomeric Repeat Binding Factor 2

Functions: Binds the telomeric double-stranded 5'-TTAGGG-3' repeat and plays a central role in telomere maintenance and protection against end-to-end fusion of chromosomes. In addition to its telomeric DNA-binding role, required to recruit a number of factors and enzymes required for telomere protection, including the shelterin complex, TERF2IP/RAP1 and DCLRE1B/Apollo. Component of the shelterin complex (telosome) that is involved in the regulation of telomere length and protection. Shelterin associates with arrays of double-stranded 5'-TTAGGG-3' repeats added by telomerase and protects chromosome ends; without its protective activity, telomeres are no longer hidden from the DNA damage surveillance and chromosome ends are inappropriately processed by DNA repair pathways. Together with DCLRE1B/Apollo, plays a key role in telomeric loop (T loop) formation by generating 3' single-stranded overhang at the leading end telomeres: T loops have been proposed to protect chromosome ends from degradation and repair. Required both to recruit DCLRE1B/Apollo to telomeres and activate the exonuclease activity of DCLRE1B/Apollo. Preferentially binds to positive supercoiled DNA. Together with DCLRE1B/Apollo, required to control the amount of DNA topoisomerase (TOP1, TOP2A and TOP2B) needed for telomere replication during fork passage and prevent aberrant telomere topology. Recruits TERF2IP/RAP1 to telomeres, thereby participating in to repressing homology-directed repair (HDR), which can affect telomere length

The "TERF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TERF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1 | TFF2 | TFF3 | TFG | TFIID Basal Transcription Factor Complex | TFIIIC2 complex | TFIP11 | TFIP11-DT | TFPI | TFPI2 | TFPT | TFR2 | TFRC | TG | TGDS | TGFA | TGFA-IT1 | TGFB1 | TGFB1I1 | TGFB2 | TGFB2-AS1 | TGFB3 | TGFBI | TGFBR1 | TGFBR2